The (table 2) . The pathways of lipoprotein formation, interconversion, and catabolism in the body are complex and will not be reviewed here. However, research over the last 10 to 15 years has indicated that the apolipoproteins play an important role in each of these processes. For example, the inability to synthesize apo B in the disorder abetalipoproteinemia prevents secretion of several lipoprotein fractions, including chylomicrons, VLDL, and LDL. In addition, apo A-I has been shown to be a cofactor for the lecithin cholesterol acyl transferase enzyme, which is responsible for synthesizing most of the cholesteryl esters in plasma, and apo CII is a cofactor for the lipoprotein lipase enzyme, which is responsible for hydrolyzing triglycerides. Finally, high-affinity lipoprotein receptors that recognize apolipoproteins B and E have been discovered. Recent research has attempted to define at the DNA level those genetically determined factors that control apolipoprotein synthesis and structure. In addition, human genetic lesions affecting apolipoprotein synthesis and structure that result in plasma lipoprotein abnormalities and in some cases premature atherosclerosis are now being identified.
that factors such as diet, weight, exercise and smoking habits are very important in determining susceptibility to cardiovascular disease. However, complex epidemiologic data and clinical observations have shown that these variables do not explain susceptibility to cardiovascular disease among all members of the population. We all know people who live to their 80s or 90s in spite of unhealthy life-styles, the so-called Winston Churchill syndrome. On the other hand, physicians often see people who maintain a reasonable diet, are not overweight, are active, and do not smoke but who suffer myocardial infarctions in their 20s, 30s, and 40s. It is clear that there must be a fundamental difference between these two groups of people. Investigators have theorized that the first group has intrinsic or genetic factors that prevent heart attacks, whereas the second group has genetic factors that result in premature heart attacks. Epidemiologic studies have shown that the levels of the cholesterol-carrying complexes in the blood, plasma lipoproteins, are strong predictors of which individuals in the population are likely to have premature heart attacks. Two of the plasma lipoproteins have been shown to play particularly strong but opposite roles. In individuals under 50 years of age elevated levels of low-density lipoprotein (LDL) and decreased levels of high-density lipoprotein (HDL) are strong predictors of heart disease. In individuals over 50 years of age LDL is less predictive, perhaps because people with extreme elevations of LDL have already died by that age, and a low HDL concentration is an even stronger predictor of heart disease. In fact, for an asymptomatic person 50 years of age an HDL measurement is the best single laboratory test to predict not only the occurrence of coronary artery disease but survival itself.
Lipoprotein metabolism and apolipoproteins
Lipoproteins are complexes of lipids and proteins ( (table 2) . The pathways of lipoprotein formation, interconversion, and catabolism in the body are complex and will not be reviewed here. However, research over the last 10 to 15 years has indicated that the apolipoproteins play an important role in each of these processes. For example, the inability to synthesize apo B in the disorder abetalipoproteinemia prevents secretion of several lipoprotein fractions, including chylomicrons, VLDL, and LDL. In addition, apo A-I has been shown to be a cofactor for the lecithin cholesterol acyl transferase enzyme, which is responsible for synthesizing most of the cholesteryl esters in plasma, and apo CII is a cofactor for the lipoprotein lipase enzyme, which is responsible for hydrolyzing triglycerides. Finally, high-affinity lipoprotein receptors that recognize apolipoproteins B and E have been discovered. Recent research has attempted to define at the DNA level those genetically determined factors that control apolipoprotein synthesis and structure. In addition, human genetic lesions affecting apolipoprotein synthesis and structure that result in plasma lipoprotein abnormalities and in some cases premature atherosclerosis are now being identified.
Modern molecular genetics
The million genes in the human genome. In addition, one would want to have enough of this material to be able to study its structure and function. As recently as 10 years ago this was an impossible task. However, with the introduction of molecular cloning, this procedure has become routine in many laboratories. The first technologic advance that allowed this to Cloned DNA can be used in many ways. cDNA clones can be used to determine mRNA structure from which the amino acid sequence of the primary translation product of a protein of interest can be deduced. Genomic clones can be used to identify aspects of gene structure such as promotors and introns. cDNA and genomic clones can be used to determine tissue levels of specific mRNAs. They can also be used to assess chromosomal localization, linkage to other genes, and disease-associated polymorphisms. Finally, they can be genetically engineered to produce altered gene products that can be used to study protein structurefunction relationships.
Strategy for isolating and characterizing the apolipoprotein genes
In our laboratory, we have isolated and are in the process of characterizing cDNA and genomic clones for four of the apolipoproteins: apo A-I, apo CII, apo CIII, and apo E. Our strategy has been to identify a region of the apolipoprotein primary amino acid sequence specified by relatively unambiguous codons. We have then synthesized cDNA oligomers corresponding to all possible mRNAs that could code for these amino acids. This mixture of oligomers is radiolabeled and used as a probe to screen a library of cDNA made from adult human liver mRNA and cloned in a plasmid vector. A cDNA clone is then radiolabeled and used as a probe to screen a library of human genomic DNA cloned in bacteriophage lambda. The selected cDNA and genomic clones are characterized by restriction endonuclease mapping, subcloning, and DNA sequencing. Chromosomal localization of the apolipoprotein genes is accomplished through the use of cDNA probes and somatic cell hybrids. In the latter technique, human and rodent cells are fused and then propagated in culture. During this process, the hybrids tend to lose human chromosomes. After a period of time, the hybrid cells contain the rodent genome and only a few human chromosomes. At that time the hybrids are characterized as to which human chromosomes are still remaining, and DNA is prepared and probed for the apoprotein gene of interest. After looking at many hybrids, one observes which human chromosome is present whenever the apoprotein gene is present and which human chromosomes are absent whenever the apoprotein gene is absent. In this way it is possible to deduce which human chromosome contains a particular apoprotein gene. Through these studies we have been able to determine that the apo A-I and apo CIII genes reside on human chromosome 11 . ' Another group has shown through family studies of the inheritance of protein polymorphisms that the apo A-IV and apo A-I genes are linked. Thus three of the apolipoprotein genes are on human chromosome 1 1. In addition, we have also shown that the genes for apo E and apo CII reside on human chromosome 19.23 I will summarize briefly our knowledge of the structure and mutations at each of these apoprotein chromosomal loci (table 3).   TABLE 3 Apolipoprotein genes
The apo A-I/apo CIII gene locus
The gene for apo A-I has been characterized4; it is approximately 2200 base pairs long and is interrupted by three intervening sequences or introns. In addition, the gene for apo CIII is very close to that for apo A-I. Studies indicate that apo A-I and apo CIII are coded for by opposite DNA strands.1 This is a very unusual configuration and may have some functional significance. In clinical studies we have examined DNA from individuals described by Norum et al.a who have very low plasma HDL levels, absence of apo A-I and apo CIII, and very severe premature atherosclerosis. We have shown that these individuals have an alteration in their apo A-I gene caused by an insertion of DNA in the region that codes for the apo A-I protein. 6' 7 This is the first demonstration of a DNA insertion causing disease in humans and is also the first demonstration at the DNA level of a genetic lesion causing atherosclerosis. In another clinical study, Rees et al.7a have found that a specific DNA alteration near the apo A-I gene was present in 50% of individuals with elevated plasma triglyceride levels and in only 5% of normal individuals. Our investigations have shown that the DNA alteration associated with the apo A-I gene is actually an alteration in the apo CIII gene.5 Our findings raise the question of whether primary abnormalities in the apo CIII gene can cause elevated triglyceride levels in humans and by this mechanism be associated with human atherosclerosis.
The apo E gene locus
We have also performed extensive studies of the apo E gene. Apo E in normolipidemic humans is distributed equally between HDL and VLDL. This apolipoprotein is involved in receptor-mediated lipoprotein recognition by cells. In addition, apo E appears to be important in the metabolism of dietary cholesterol, since it has been observed in both animals and humans that the ingestion of dietary cholesterol leads to the appearance of unusual lipoproteins that are rich in apo (table 4) . Through this work it is now possible to construct DNA probes that recognize the normal apo E allele as well as each of the mutant apo E alleles. Therefore it is now possible to screen for mutant apo E alleles in the population with DNA probes.
Summary
These types of studies lay the foundation for understanding the human apolipoproteins at the genetic level. In addition, through a few specific examples, we have already shown evidence at the DNA level that lesions in apolipoprotein genes can play a role in human atherosclerosis. This work is in its infancy, but we hope it will have a major impact on our ability to understand genetic susceptibility to atherosclerosis in the general population.
